First Department of Internal Medicine, Gifu University Hospital.
Department of Gastroenterology, Gifu Prefectural General Medical Center.
Surg Laparosc Endosc Percutan Tech. 2020 Jun;30(3):257-262. doi: 10.1097/SLE.0000000000000771.
Intestinal perforation is a severe adverse event during pancreaticobiliary endoscopy. The use of over-the-scope clip (OTSC) has recently increased; however, the efficacy of OTSC during pancreaticobiliary endoscopy has not been well studied.
To evaluate the efficacy of OTSC for the closure of gastrointestinal iatrogenic perforation during pancreaticobiliary endoscopy.
This was a retrospective multicenter cohort study conducted at 3 tertiary care centers. The inclusion criteria were patients who had gastrointestinal perforation during endoscopic procedures for pancreaticobiliary diseases and underwent perforation closure using OTSC. The primary outcome was the clinical success rate. Secondary outcomes were technical success rates, adverse event rates, and the duration until the start of oral intake after OTSC.
Ten patients were treated by OTSC from January 2013 to December 2017. In 2 out of 10, the perforations could not be closed completely. In the remaining 8, perforations were closed completely, but intestinal obstruction caused by OTSC occurred in 1 patient. The clinical success rate was 80% (8/10). The technical and adverse event rates were 80% (8/10) and 10% (1/10), respectively. A median resumption timing of oral intake was 5 days (range, 3 to 10 d).
OTSC is considered as effective management for perforations during pancreaticobiliary endoscopy, although careful consideration is required for the indication of OTSC.
肠穿孔是胰腺胆道内镜检查中的一种严重不良事件。过内镜用全覆膜食管-胃-十二指肠支架(OTSC)的使用最近有所增加,但在胰腺胆道内镜检查中 OTSC 的疗效尚未得到很好的研究。
评估 OTSC 在胰腺胆道内镜检查中用于闭合医源性胃肠道穿孔的疗效。
这是一项在 3 家三级护理中心进行的回顾性多中心队列研究。纳入标准为因胰腺胆道疾病而行内镜检查时发生胃肠道穿孔且使用 OTSC 进行穿孔闭合的患者。主要结局是临床成功率。次要结局是技术成功率、不良事件发生率以及 OTSC 后开始口服摄入的时间。
2013 年 1 月至 2017 年 12 月期间,10 例患者接受了 OTSC 治疗。在 10 例中,有 2 例穿孔不能完全闭合。在其余 8 例中,穿孔完全闭合,但 1 例发生 OTSC 引起的肠梗阻。临床成功率为 80%(8/10)。技术成功率和不良事件发生率分别为 80%(8/10)和 10%(1/10)。中位开始口服摄入的时间为 5 天(范围,3-10 d)。
OTSC 被认为是胰腺胆道内镜检查中穿孔的有效治疗方法,但需要仔细考虑 OTSC 的适应证。